metformin has been researched along with Carcinoma, Neuroendocrine in 2 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Carcinoma, Neuroendocrine: A group of carcinomas which share a characteristic morphology, often being composed of clusters and trabecular sheets of round blue cells, granular chromatin, and an attenuated rim of poorly demarcated cytoplasm. Neuroendocrine tumors include carcinoids, small (oat) cell carcinomas, medullary carcinoma of the thyroid, Merkel cell tumor, cutaneous neuroendocrine carcinoma, pancreatic islet cell tumors, and pheochromocytoma. Neurosecretory granules are found within the tumor cells. (Segen, Dictionary of Modern Medicine, 1992)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metformin is an anti-hypoglycemic drug that appears to have anticancer effects." | 1.56 | Metformin Inhibits Proliferation and Tumor Growth of QGP-1 Pancreatic Neuroendocrine Tumor Cells by Inducing Cell Cycle Arrest and Apoptosis. ( Fujihara, S; Fujita, K; Fujita, N; Iwama, H; Kamada, H; Kato, K; Kobara, H; Kobayashi, K; Masaki, T; Morishita, A; Namima, D; Tsutsui, K; Yamana, H, 2020) |
| "Treatment with metformin was associated with inhibition of mTOR/p70S6K/pS6 signaling and downregulation of pERK in both TT and MZ-CRC-1 cells." | 1.38 | Metformin inhibits growth and decreases resistance to anoikis in medullary thyroid cancer cells. ( Bauer, A; Burman, KD; Costello, J; Hoperia, V; Jensen, K; Klubo-Gwiezdzinska, J; Patel, A; Vasko, V; Wartofsky, L, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yamana, H | 1 |
| Kato, K | 1 |
| Kobara, H | 1 |
| Fujihara, S | 1 |
| Fujita, K | 1 |
| Namima, D | 1 |
| Fujita, N | 1 |
| Kobayashi, K | 1 |
| Kamada, H | 1 |
| Morishita, A | 1 |
| Tsutsui, K | 1 |
| Iwama, H | 1 |
| Masaki, T | 1 |
| Klubo-Gwiezdzinska, J | 1 |
| Jensen, K | 1 |
| Costello, J | 1 |
| Patel, A | 1 |
| Hoperia, V | 1 |
| Bauer, A | 1 |
| Burman, KD | 1 |
| Wartofsky, L | 1 |
| Vasko, V | 1 |
2 other studies available for metformin and Carcinoma, Neuroendocrine
| Article | Year |
|---|---|
Metformin Inhibits Proliferation and Tumor Growth of QGP-1 Pancreatic Neuroendocrine Tumor Cells by Inducing Cell Cycle Arrest and Apoptosis.
Topics: Apoptosis; Biomarkers; Carcinoma, Neuroendocrine; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Pro | 2020 |
Metformin inhibits growth and decreases resistance to anoikis in medullary thyroid cancer cells.
Topics: AMP-Activated Protein Kinase Kinases; Anoikis; Antineoplastic Agents; Carcinoma, Neuroendocrine; Cel | 2012 |